Document Detail

Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study.
MedLine Citation:
PMID:  15364747     Owner:  NLM     Status:  MEDLINE    
PURPOSES: We studied the use of perioperative IV and oral administration of amiodarone for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass graft surgery (CABG). BACKGROUND: In the United States, > 500,000 patients undergo CABG each year. Numerous studies to date have suggested that postoperative atrial fibrillation occurs in 30 to 50% of patients, leading to significant morbidity, including hypotension, heart failure, thromboembolic complications, prolonged hospital stay, and increased hospital costs. The objective of this study was to assess the use of IV amiodarone in combination with oral amiodarone to reduce the incidence of postoperative atrial fibrillation. METHOD: From January 1999 to October 1999, 51 patients scheduled for CABG were randomly selected for participation in the amiodarone administration trial. IV amiodarone, 0.73 mg/min, was administered on call to the operating room for 48 h, followed by oral amiodarone, 400 mg q12h, for the next 3 days. The amiodarone group was case-control matched to the incidence of postoperative atrial fibrillation in 92 patients undergoing CABG using conventional medical therapy during the same period. The primary end point of this study was the incidence of postoperative atrial fibrillation, length of hospital stay, and hospital costs, compared to the control group undergoing CABG during the same time. RESULTS: Atrial fibrillation occurred in 3 of 51 patients (5.88%) in the amiodarone group, compared to 24 of 92 patients (26.08%) in the control group. Length of hospital stay in the amiodarone group was less than in the control group (5.3 days vs 6.7 days), with a trend toward decrease in hospital costs. CONCLUSION: The administration of IV amiodarone in conjunction with oral amiodarone for a total dose of 4,500 mg over 5 days appears to be a hemodynamically well-tolerated, safe, and effective treatment in decreasing the incidence of postoperative atrial fibrillation, shortening length of stay, and a trend toward lowering hospital costs, even in patients with significantly reduced left ventricular function (< 30%). A large multicenter study using IV and oral amiodarone should be pursued prior to deciding whether its use should become standard therapy in all patients undergoing CABG in order to decrease the incidence of postoperative atrial fibrillation.
Joshua Kerstein; Ajay Soodan; Mehdi Qamar; Mazhar Majid; Edgar Lichstein; Gerald Hollander; Jacob Shani
Related Documents :
15364747 - Giving iv and oral amiodarone perioperatively for the prevention of postoperative atria...
8557917 - Classification of death in antiarrhythmia trials.
7724387 - Safety of antitachycardia pacing in patients with implantable cardioverter defibrillato...
16722587 - Does prophylactic sotalol and magnesium decrease the incidence of atrial fibrillation f...
21883647 - Twenty years of clinical experience with a new modality of vascular-targeted photodynam...
21447907 - Preoperative treatment with botulinum toxin a before total hip arthroplasty in a patien...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Chest     Volume:  126     ISSN:  0012-3692     ISO Abbreviation:  Chest     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-09-14     Completed Date:  2004-11-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  716-24     Citation Subset:  AIM; IM    
Maimonides Medical Center, 953 49th St, Brooklyn, NY 11219, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Amiodarone / administration & dosage*,  adverse effects,  economics
Anti-Arrhythmia Agents / administration & dosage*,  adverse effects,  economics
Atrial Fibrillation / economics,  prevention & control*
Case-Control Studies
Coronary Artery Bypass* / economics
Coronary Artery Disease / economics,  surgery*
Cost Savings / statistics & numerical data
Dose-Response Relationship, Drug
Drug Administration Schedule
Electrocardiography / drug effects
Hemodynamics / drug effects
Hospital Charges / statistics & numerical data
Infusions, Intravenous
Length of Stay / economics
Middle Aged
Myocardial Reperfusion Injury / prevention & control*
Postoperative Complications / economics,  prevention & control*
Premedication / economics
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 1951-25-3/Amiodarone
Comment In:
Chest. 2004 Sep;126(3):662-4   [PMID:  15364735 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mitral valve repair in patients with low left ventricular ejection fractions: early and late results...
Next Document:  Long-term survival after videothoracoscopic lobectomy for stage I lung cancer.